NCT04244331|Terminated
Study Stopped
Low recruitment
DETERMINATION OF THE CELL OF ORIGIN (COO) in LDCGB
GELTAMO-COO
Loading search results
Sponsor study identifier
observational
159
1 country
1
Study Start
May 1, 2018
Actual (reported)Primary Completion
May 1, 2019
Actual (reported)Study Completion
March 1, 2020
Actual (reported)This is a prospective, multicenter study, without any therapeutic intervention that will consist of the analysis of the results of the determination of the COO of all the patients diagnosed with LDCGB in the Spanish hospitals of GELTAMO that adhere to the project. The determination of the COO will be carried out prospectively at the Genomic Unit of the Hospital Clínic de Barcelona (IDIBAPS), where the histological samples of the patients will be sent for this purpose. The main study variable will be the description of the COO (germ-center origin \[GCB\], activated \[ABC\], NOT DETERMINABLE, NOT VALUABLE)
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 1, 2018
Actual (reported)May 1, 2019
Actual (reported)January 24, 2020
Actual (reported)January 28, 2020
Actual (reported)March 1, 2020
Actual (reported)Develop Patform
The objective of the study is to develop a platform for the determination of the COO at a national level by means of NanoString in patients diagnosed with LDCGB and to analyze the distribution of this COO.
2 years
Integration CCO
2 years
Determination CCO
15 days
Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients diagnosed with LDCGB an Age over or equal to 18 years old.
GELTAMO
Madrid, 28040, Spain
TUMMORAL BIOPSIA
159 participants (actual enrollment reported by the registry).
First Submitted
January 24, 2020
First Posted
January 28, 2020
Study Start
May 1, 2018
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
May 1, 2019
Actual (reported)Study Completion
March 1, 2020
Actual (reported)Last Updated
February 26, 2024
Record last verified: 2021-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: